0001209191-19-012090.txt : 20190221
0001209191-19-012090.hdr.sgml : 20190221
20190221165124
ACCESSION NUMBER: 0001209191-19-012090
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20190219
FILED AS OF DATE: 20190221
DATE AS OF CHANGE: 20190221
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: SALKA SUSAN R
CENTRAL INDEX KEY: 0001158584
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-16753
FILM NUMBER: 19622558
MAIL ADDRESS:
STREET 1: 14778 EL RODEO CT.
CITY: RANCHO SANTA FE
STATE: CA
ZIP: 92067
FORMER NAME:
FORMER CONFORMED NAME: NOWAKOWSKI SUSAN
DATE OF NAME CHANGE: 20010904
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: AMN HEALTHCARE SERVICES INC
CENTRAL INDEX KEY: 0001142750
STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-HELP SUPPLY SERVICES [7363]
IRS NUMBER: 061500476
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 12400 HIGH BLUFF DRIVE
STREET 2: SUITE 100
CITY: SAN DIEGO
STATE: CA
ZIP: 92130
BUSINESS PHONE: 8668718519
MAIL ADDRESS:
STREET 1: 12400 HIGH BLUFF DRIVE
STREET 2: SUITE 100
CITY: SAN DIEGO
STATE: CA
ZIP: 92130
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2019-02-19
0
0001142750
AMN HEALTHCARE SERVICES INC
AMN
0001158584
SALKA SUSAN R
8840 CYPRESS WATERS BLVD., SUITE 300
COPPELL
TX
75019
1
1
0
0
President and CEO
Common Stock
2019-02-19
4
A
0
15729
0.00
A
203615
D
Common Stock
2019-02-19
4
F
0
6189
55.54
D
197426
D
Common Stock
2019-02-19
4
M
0
10172
0.00
A
207598
D
Common Stock
2019-02-19
4
F
0
4002
55.54
D
203596
D
Common Stock
2019-02-19
4
M
0
6742
0.00
A
210338
D
Common Stock
2019-02-19
4
F
0
2652
55.54
D
207686
D
Restricted Stock Units
2019-02-19
4
M
0
10172
0.00
D
Common Stock
10172
9872
D
Restricted Stock Units
2019-02-19
4
M
0
6742
0.00
D
Common Stock
6742
13687
D
The acquisition of Common Stock set forth in this row resulted from the vesting of a Performance Restricted Stock Unit ("PRSU") award granted by the Company on January 5, 2016. The ultimate number of PRSUs that could have been earned and vested under this award depended on the Company achieving or exceeding, on a consolidated basis, a certain specified adjusted earnings before interest, taxes, depreciation and amortization, divided by gross revenue and expressed as a percentage ("Adjusted EBITDA Margin") as of December 31, 2018 for the one-year period beginning on January 1, 2018 and ended December 31, 2018. As a result, 77.50% of the target amount of PRSUs for this award were deemed earned and vested.
Number of shares withheld for tax purposes.
Common Stock acquired on the vesting of Restricted Stock Units ("RSUs").
Common Stock acquired on the vesting of RSUs.
The RSUs identified in this row were granted pursuant to the AMN Healthcare Equity Plan. Each RSU represents a contingent right to receive one share of AMN Common Stock.
The RSUs identified in this row were granted on December 5, 2016 and vest on the third anniversary of the grant date, provided, however, the RSUs shall vest on an accelerated basis thirteen months after the grant date, in the incremental amount of 33%, should the Company achieve or exceed a certain specified earnings before interest, taxes, depreciation and amortization (EBITDA) target for the 2017 fiscal year, and on the second anniversary of the grant date, in the amount of 34%, should the Company achieve or exceed the specified EBITDA target for the 2018 fiscal year.
RSUs do not have an expiration date.
The RSUs identified in this row were granted pursuant to the AMN Healthcare 2017 Equity Plan. Each RSU represents a contingent right to receive one share of AMN Common Stock.
The RSUs identified in this row were granted on December 19,2017 and vest on the third anniversary of the grant date, provided, however, the RSUs shall vest on an accelerated basis thirteen months after the grant date, in the incremental amount of 33%, should the Company achieve or exceed a certain specified earnings before interest, taxes, depreciation and amortization (EBITDA) target for the 2018 fiscal year, and on the second anniversary of the grant date, in the amount of 34%, should the Company achieve or exceed the specified EBITDA target for the 2019 fiscal year.
/s/ Susan R. Salka
2019-02-21